Trandolapril, >=98% (HPLC), white powder

Not available outside of the UK & Ireland.

Application

Trandolapril has been used as an angiotensin-converting enzyme (ACE) inhibitor to study its effects on responsiveness of human retinal endothelial cells (HRECs) to vascular endothelial growth factor (VEGF).

Biochem/physiol Actions

Trandolapril is an ACE inhibitor. Trandolapril differs from other ACE inhibitors in that it has a longer biological half-life and a high degree of lipophilicity.

Studies have reported that trandolapril inhibits atherosclerosis¹ and decreases the occurrence of atrial fibrillation².

Features and Benefits

This compound was developed by Abbott. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.

Other Notes

Tandem Mass Spectrometry data independently generated by Scripps Center for Metabolomics is available to view or download in PDF. T4827.pdf Tested metabolites are featured on Scripps Center for Metabolomics METLIN Metabolite Database. To learn more, visit sigma.com/metlin.

Packaging

10, 50 mg in glass bottle

Preparation Note

Trandolapril is soluble in DMSO at a concentration that is greater than or equal to 20 mg/ml.